Dementia

Demantia treatments are minimally effective, and the prevalence of various forms of Dementia (such as AD, FTD, DLB, PSP) is projected to increase substantially by 2050. Comprehensive clinical trials for Dementia are imperative, and that's precisely our focus.

Drawing from extensive expertise in clinical trials and pharmaceutical development across different phases, Julius Clinical is well-equipped to facilitate investigator-initiated trials, observational studies, or the integration of real-world data in dementia research. 

Meet our Dementia Scientific Advisory Board

Prof. dr. Philip Scheltens is a renowned cognitive neurologist, known for his extensive contributions to dementia research. He founded the Alzheimer Center at Amsterdam University Medical Centers and has led numerous studies and clinical trials. Scheltens has authored over 1250 peer-reviewed papers, received prestigious awards such as the European Grand Prix for Alzheimer’s Research, and been knighted by the King of the Netherlands. He has chaired important initiatives like the Dutch National Plan against dementia and currently leads the World Dementia Council. In 2023, he was honored with the Bengt Winblad Lifetime Achievement Award.

Meet our Dementia Scientific Advisory Board

Professor John Harrison, Chief Scientific Officer at Scottish Brain Sciences, is a renowned cognition expert with 25 years of experience in aiding over 80 CNS drug development organizations. His contributions include developing the Neuropsychological Test Battery for Alzheimer’s studies and playing a pivotal role in Brintellix’s development and registration. As an Associate Professor at Amstedan UUM – Alzheimer Center and Visiting Professor at King’s College London, he holds Chartered Psychologist status and has authored over 100 books and scientific articles.

Brain Clinical is Julius Clinical’s proprietary network, which covers 13 countries, for CNS clinical trials. This network includes highly experienced and devoted researchers who specialize in streamlined and rigorously executed clinical trials for Dementia treatments.


We’re proud partner of

We work closely with the Brain Research Center in the Netherlands, which specialises in high-quality clinical trial execution and scientific publication.

Read more

We also have a close partnership and short lines of communication with Amsterdam Neuroscience, with whom we integrate basic, translational, and clinical research into trials.

Read more

Dementia Forum UK provides a vital platform for collaboration and innovation in addressing the challenges of dementia.

Read more

Julius Clinical has a proven track record of operational excellence developing innovative solutions in Dementia clinical studies. An example of one of our Alzheimer’s studies is the completed SAPHIR.

SAPHIR phase IIa

Completed

24 patients | 7 countries | 120 sites

Multicentre Project to assess the Safety and Tolerability of Treatment in Subjects with early stage Alzheimer’s Disease.

Phase III European

240 patients | 5 countries | 30 sites

Study to assess safety and efficacy in patients with mild cognitive impairment to mild dementia due to Alzheimer’s Disease.

Phase II Netherlands

Ongoing

13 patients | 1 country | 1 site

An EEG study to evaluate synaptic activity in subjects with mild to moderate Alzheimer’s Disease.

Phase II

Ongoing

200 patients | 7 countries | 36 sites

Multi-center study to evaluate the efficacy and safety in patients with mild cognitive impairment due to Alzheimer’s Disease or mild Alzheimer’s Disease.


Expert team

Planning and executing complex Dementia clinical studies requires specific scientific and operational expertise. Julius Clinical brings these together in a cohesive team that understands Dementia standards of care and the nuances of effectively running clinical trials in this area.

Lieza exalto
Maria papakrasa

Related webinars

The Alzheimer’s disease drug development landscape

Hosted by: Julius Clinical.Speakers:Pieter van Bokhoven | CSO| IAO Amsterdam Neuroscience AUMC Jort Vijverberg | Neurologist | Amsterdam Neuroscience AUMCTopics that are discussed during this webinar:All major trends in Alzh...

Speakers: Dr. Jort Vijverberg

Innovative Endpoints in Alzheimer’s Disease Clinical Trials

Together with our partner Brain Research Center, we presented the webinar: Innovative Endpoints in Alzheimer’s Disease Clinical trials.During this webinar, two experts in the field, Dr. Niels Prins and Dr. Jort Vijverberg discussed the ...

Speakers: Dr. Jort Vijverberg

Dementia scientific insights

Explore our Dementia trial capabilities, case studies, and other resources.

Download

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn